Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Low-dose ketamine is used as analgesic for acute and chronic pain. It is metabolized in the liver to norketamine via cytochrome P450 (CYP) enzymes. There are few human data on the involvement of CYP enzymes on the elimination of norketamine and its possible contribution to analgesic effect. The aim of this study was to investigate the effect of CYP enzyme induction by rifampicin on the pharmacokinetics of S-ketamine and its major metabolite, S-norketamine, in healthy volunteers. Methods: Twenty healthy male subjects received 20 mg/70 kg/h (n = 10) or 40 mg/70 kg/h (n = 10) intravenous S-ketamine for 2 h after either 5 days oral rifampicin (once daily 600 mg) or placebo treatment. During and 3 h after drug infusion, arterial plasma concentrations of S-ketamine and S-norketamine were obtained at regular intervals. The data were analyzed with a compartmental pharmacokinetic model consisting of three compartments for S-ketamine, three sequential metabolism compartments, and two S-norketamine compartments using the statistical package NONMEM® 7 (ICON Development Solutions, Ellicott City, MD). Results: Rifampicin caused a 10% and 50% reduction in the area-under-the-curve of the plasma concentrations of S-ketamine and S-norketamine, respectively. The compartmental analysis indicated a 13% and 200% increase in S-ketamine and S-norketamine elimination from their respective central compartments by rifampicin. Conclusions: : A novel observation is the large effect of rifampicin on S-norketamine concentrations and indicates that rifampicin induces the elimination of S-ketamine's metabolite, S-norketamine, probably via induction of the CYP3A4 and/or CYP2B6 enzymes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pfenninger, E. G., Durieux, M. E., & Himmelseher, S. (2002) · Anesthesiology · doi:10.1097/00000542-200202000-00022 · Cited by 189
Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man
Schüttler, J., Stanski, D. R., White, P. F., Trevor, A. J., Horai, Y., Verotta, D., & Sheiner, L. B. (1987) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01066320 · Cited by 178
Investigating the pharmacodynamics of ketamine in children
HERD, D. W., ANDERSON, B. J., KEENE, N. A., & HOLFORD, N. H. G. (2008) · Pediatric Anesthesia · doi:10.1111/j.1460-9592.2007.02384.x · Cited by 103
Cited by
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711
“Another way directly transforms ketamine into hydroxy-ketamine (5%) [7].”
BackgroundKetamine: A Review of Clinical Pharmacokinetics and Pharmacodynamics in Anesthesia and Pain Therapy
Peltoniemi, M. A., Hagelberg, N. M., Olkkola, K. T., & Saari, T. I. (2016) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0383-6 · Cited by 672
Ketamine for chronic pain: risks and benefits
Niesters, M., Martini, C., & Dahan, A. (2014) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.12094 · Cited by 508
Self-citationKetamine applications beyond anesthesia – A literature review
Nowacka, A., & Borczyk, M. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172547 · Cited by 129
Stereoselective and regiospecific hydroxylation of ketamine and norketamine
Desta, Z., Moaddel, R., Ogburn, E. T., Xu, C., Ramamoorthy, A., Venkata, S. L. V., Sanghvi, M., Goldberg, M. E., Torjman, M. C., & Wainer, I. W. (2012) · Xenobiotica · doi:10.3109/00498254.2012.685777 · Cited by 114
“Metabolic drug interactions involving (R,S)Ket and (S)-Ket have previously been reported involving medetomidine (Kharasch et al. 1992), dexmedeomidine (Nama et al. 2010) and rifampicin (Noppers et al. 2011) and Ket itself has been shown to induce CYPs in rats (Chan et al. 2005; Chen & Chen 2010).”
Metadata
- Authors
- Noppers, I., Olofsen, E., Niesters, M., Aarts, L., Mooren, R., Dahan, A., Kharasch, E., & Sarton, E.
- Venue
- Anesthesiology
- Published
- 2011-06-01
- Volume
- 114
- Issue
- 6
- Pages
- 1435-1445
- ISSN
- 0003-3022 (ISSN-L)
- OpenAlex
- W2022879463
- Cited by
- 57
- References
- 3
- FWCI
- 5.26
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration. https://app.cochat.ai/papers/10.1097/aln.0b013e318218a881
- The paper
- Noppers, I., Olofsen, E., Niesters, M., Aarts, L., Mooren, R., Dahan, A., Kharasch, E., & Sarton, E. (2011). Effect of Rifampicin on S-ketamine and S-norketamine Plasma Concentrations in Healthy Volunteers after Intravenous S-ketamine Administration. Anesthesiology. https://doi.org/10.1097/aln.0b013e318218a881
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.